Recent advances in cardiovascular research increasingly recognize the gut microbiome as a pivotal factor influencing cardiovascular disease (CVD) pathogene | Drug Discovery And Development ...

44 Human SH-SY5Y neuroblastoma cells were treated with captopril, enalapril or enalaprilat, or saralasin. In all cases, statistically significant reductions in cell growth were seen over 5 days of ...

However, use of enalapril or captopril was associated with higher mortality compared with ramipril: adjusted hazard ratios (and 95% CIs) were 1.10 (1.04–1.16) for enalapril and 1.13 (1.01–1.26) for ...

enalapril, 0.99; 95% CI ... when only half the full dose of valsartan was added to an evidence-based dose of captopril in patients after myocardial infarction. 7 Collectively, these findings ...

Goldstein has reviewed the results of four double-blind comparative trials in which 368 patients were treated with quinapril and 338 with comparative therapies (i.e. captopril, enalapril or placebo).

Patients receiving conventional therapy were randomly assigned, 0.5 to 10 days after acute myocardial infarction, to additional therapy with valsartan (4909 patients), valsartan plus captopril ...

In patients treated with enalapril and aspirin, the relative risk of death at the end of the study was 1.23 (95% confidence interval [CI], 0.99-1.53) compared with 0.86 (95% CI, 0.63-1.16) for ...